Medtronic plc
NYSE: MDT·Galway, Ireland·CIK 0001613103
- Price
- $102.88
- Base IV
- $66.42
Valuation snapshot
At $102.88, the price sits between our base case ($66.42) and bull case ($103.22).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $66.42
- 65% of the price · range $34.35–$103.22
- Price vs base case
- 55% above
- $102.88 against $66.42
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $34.35 to bull $103.22. Values per share.
Price against each value
- Bear case
- $34.35
- Price 199% above
- No growth
- …
- —
- Base case
- $66.42
- Price 55% above
What does Medtronic do?
Medtronic develops and sells medical devices and information systems for the diagnosis and management of heart rhythm disorders, heart failure, and other cardiovascular conditions.
It brought in $37.5B of sales in the 12 months to Jul 2026.
- Industry
- Healthcare
- Based in
- Galway, Ireland
- Trades on
- NYSE as MDT
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Jul 2026, about 14¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 35¢ of every dollar.
- Making what it sells35¢
- Research and development8¢
- Sales, marketing and admin32¢
- Everything else it takes to operate7¢
- Tax4¢
- Left as profit14¢
Who pays Medtronic, and for what?
Medtronic develops, manufactures, and sells medical devices, therapies, and related services worldwide. Its products treat heart, neurological, surgical, monitoring, and diabetes conditions, and it earns revenue mainly from sales to healthcare providers and systems.
Hospitals, healthcare systems, physicians, ambulatory surgery centers, distributors, and other care providers pay for its products and services.
Cardiovascular
38%Heart-rhythm, cardiac-ablation, heart-valve, aortic, coronary, peripheral vascular, and related care-management products and services.
Neuroscience
28%Spine, cranial, neurovascular, ear-nose-throat, pelvic-health, neuromodulation, and implantable drug-delivery products.
Medical Surgical
24%Surgical, endoscopy, robotic-assisted surgery, wound-care, airway-management, and patient-monitoring products.
Medtronic Hugo robotic-assisted surgery systemImage: Medtronic Diabetes
9%Insulin pumps, continuous glucose-monitoring systems, and related consumables; the business completed its IPO as MiniMed in March 2026.
MiniMed insulin pump and glucose-monitoring systemImage: Medtronic
Where its work physically happens, beyond headquarters:
- Tolochenaz manufacturing campus — Tolochenaz, Switzerland. The site produces implantable cardiac devices at a reported rate of about 2,000 per day, making it a major source of pacemakers and defibrillators.
- Galway pulsed field ablation site — Galway, Ireland. FDA approval of this additional manufacturing site increased supply of Affera pulsed field ablation products during a period of strong demand.
- North Haven manufacturing facility — North Haven, United States. Medtronic describes this 1,500-person plant as one of its largest manufacturing facilities, producing surgical products including sutures.
- Tempe microelectronics campus — Tempe, United States. The campus manufactures microelectronics used in Medtronic pacemakers, defibrillators and neurostimulators.
- Medtronic Engineering and Innovation Center — Hyderabad, India. Medtronic's largest R&D center outside the United States supports global product development through software, systems, hardware and quality engineering.
How is the business doing?
Sales grew from $30.1B in 2021 to $36.4B in 2026, about 4% a year.
Running the business leaves about 18¢ of each sales dollar as operating profit, up from 15¢ in 2021.
After paying for its upkeep and new investment, it had $6.1B of cash to spare in the 12 months to Jul 2026.
What does management say it's aiming for?
Medtronic says it exists to use biomedical engineering to reduce pain, restore health, and extend life.
“to alleviate pain, restore health, and extend life”
What management says it is working on now:
Accelerate innovation-driven growth
Management is emphasizing new products, a strong pipeline, acquisitions, and wider adoption of its technologies in large healthcare markets.
Medtronic FY2026 Form 10-K, Item 1Improve patient and provider outcomes
The company is focused on therapies and partnerships that make care more effective, easier to use, and simpler for healthcare providers to deploy.
Medtronic FY2026 Form 10-K, Item 1Apply data, AI, and automation
Medtronic is working to use data, artificial intelligence, remote monitoring, and automation to tailor treatment and improve care delivery.
Medtronic FY2026 Form 10-K, Item 1Scale newer growth platforms
Recent management commentary highlights growth platforms in electrophysiology, spine-enabling technology, pelvic health, acute care, and robotic-assisted surgery.
Medtronic reports first quarter fiscal 2027 resultsInvest selectively while managing costs
Management says it is combining investments in innovation, portfolio development, and commercial execution with disciplined financial management.
Medtronic reports first quarter fiscal 2027 results
- Organic revenue growth, Fiscal 2027
- 7.25% to 7.75%
- Medtronic reports first quarter fiscal 2027 results
- Diluted non-GAAP earnings per share, Fiscal 2027
- $5.94 to $6.00
- Medtronic reports first quarter fiscal 2027 results
What's changing right now?
Growth is picking up. In Q1 2027 it sold 14% more than a year earlier. The year before, quarters averaged 8%.
Its operating margin is wider than a year ago: 18¢ per sales dollar, against 17¢.
Since Oct 2026 the share price has risen 11%, from $93.03 to $102.88.
Recently
April 24, 2026
R&D expense as % of revenue, annual changed to 7.9%
Medtronic Form 10-K FY2026April 24, 2026
Cardiovascular portfolio revenue, annual changed to $14.0B
Medtronic Form 10-K FY2026
Coming up
Expected in future periods
Sphere-360 and Sphere-9 expansion
Medtronic expects further commercialization of its Sphere-360 pulsed-field ablation catheter and expansion of Sphere-9 into ventricular-arrhythmia treatment.
Medtronic FY2026 Form 10-K, Item 7Expected in future periods
Stealth AXiS and spine technology adoption
The company expects broader adoption of Stealth AXiS, AiBLE, Mazor robotics, and AI-assisted spine-planning technologies across spinal and related procedures.
Medtronic FY2026 Form 10-K, Item 7Expected in future periods
Hugo robotic-assisted surgery expansion
Medtronic expects continued adoption of Hugo and Touch Surgery, including additional U.S. indications and broader use in urologic, gynecologic, bariatric, hernia, and general surgery.
Medtronic FY2026 Form 10-K, Item 7Next fiscal 2027 quarterly report; date to be announced by the company
Fiscal 2027 performance update
The next quarterly results will show whether recent growth platforms and the raised fiscal 2027 guidance are continuing to develop.
Medtronic Investor Relations, Events and Presentations
Our own estimate moved too: the base case went from $55.65 to $66.42 a share between our last two valuations. The biggest reason: Cardiovascular portfolio revenue, annual moved from an unreported prior value to $14.0B, as reported in Medtronic Form 10-K FY2026.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Strong competition and price pressure
Medtronic competes with large and specialized device makers, pharmaceutical companies, and alternative therapies. Hospital consolidation, tenders, and cost controls can pressure prices, revenue, and market share.
From the company's own filingsWould hit how fast sales growMedtronic FY2026 Form 10-K, Item 1A
Regulatory and reimbursement changes
Product approvals, quality reviews, privacy rules, and healthcare-payment policies can change across countries. Delays, recalls, penalties, or reduced reimbursement could limit sales or increase costs.
From the company's own filingsWould hit how fast sales growMedtronic FY2026 Form 10-K, Items 1 and 1A
Product quality and execution
Manufacturing problems, product defects, recalls, supply interruptions, or delays in scaling new products could reduce sales, damage trust, and increase expenses.
From the company's own filingsWould hit how much of each sale it keepsMedtronic FY2026 Form 10-K, Item 1A
Technology and innovation risk
Growth depends on developing, approving, manufacturing, and commercializing differentiated products. Medtronic may fail to integrate or scale AI and digital technologies as quickly as competitors.
From the company's own filingsWould hit how fast sales growMedtronic FY2026 Form 10-K, Item 1A
Supply chain and tariff exposure
Sole-source components, sterilization capacity, commodity prices, tariffs, and geopolitical disruptions could interrupt production or raise costs. Management estimated a possible $250 million pre-tax tariff impact for fiscal 2027 based on rates known in June 2026.
From the company's own filingsWould hit how much of each sale it keepsMedtronic FY2026 Form 10-K, Item 7
Debt and transaction risks
Debt service uses cash that could otherwise fund growth. Acquisitions, divestitures, and the Diabetes separation may also create integration costs, delays, liabilities, or operational complexity.
From the company's own filingsWould hit how much it has to reinvestMedtronic FY2026 Form 10-K, Item 1A
Full fiscal year revenue grew only 3.6% in FY2024 and 3.6% in FY2025, demonstrating historical susceptibility to product cycle pauses.
From our researchWould hit how fast sales growMedtronic Form 10-K FY2025
A heavy debt load
It owes $26.5B more than it holds in cash, about 3.9 years of operating profit.
From the numbers
Is it a good business?
From 2017 to 2026 it earned between 5% and 8% on the capital invested in it, a median of 6%. Its cost of capital in the latest valuation is 7.3%; returns were above it in 2 of the 10 years.
From 2017 to 2026 it earned between 6% and 10% on its shareholders' equity, a median of 9%.
Over 10 years its operating margin ranged from 15¢ to 22¢ per sales dollar, a median of 18¢. Gross margin ran from 65¢ to 70¢.
Cost of capital 7.3%
The number of shares has held roughly steady over the past year.
It owes $26.5B more than it holds in cash, about 3.9 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $102.88. Our put its value between $34.35 and $103.22, with $66.42 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $34.35
In this scenario, Medtronic faces stiffening competition in cardiac devices and surgical tools, pulling sales growth back to its historical 3% average while global tax changes keep profit margins near 16.5%.
Base case, $66.42
In this scenario, Medtronic maintains steady mid-single-digit sales growth supported by new heart and diabetes devices, while cost efficiencies lift profit margins slightly to 18.5%.
Bull case, $103.22
In this scenario, Medtronic sustains its recent double-digit growth momentum across heart therapies and diabetes technology, driving profit margins above 20% through manufacturing scale and high-margin sensor sales.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 55%
For Medtronic to be worth today's $102.88, sales would need to grow about 13.8% a year. We assume 5.5%. Over the last 5 years, sales grew 3.5% a year.
Or, if sales grow 5.5% as we assume, the price works with a profit margin of 26.3% (we assume 18.5%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 13.8% a year?
Try your own numbersWe're moderately sure of this range: it scores 65 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $66.42 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.5%
- Operating margin18.5%
- Long-term growth rate2.8%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$66.42 -35.4%


